Atracurium Besylate: Precautions and Warnings

 

Atracurium Besylate is a nondepolarizing neuromuscular blocker, also known as an immune suppressor. Atracurium Besylate is used in the treatment of lymphoma, multiple myeloma, leukaemia, ovarian cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma. Atracurium Besylate is supplied in 25 mg in 2.5ml single-use vials to administer intravenously. One should read the warnings and precautions associated with Atracurium Besylate, such as: 

Atracurium Besylate has been associated with residual paralysis. Patients with neuromuscular diseases and carcinomatosis may be at higher risk of residual paralysis. To prevent complications resulting from Atracurium Besylate-associated residual paralysis, extubation is recommended only after the patient has recovered sufficiently from neuromuscular blockade.

Serious adverse reactions, including “gasping syndrome”, can happen in neonates and infants treated with benzyl alcohol-preserved drugs, including Atracurium Besylate. When prescribing the doses of Atracurium Besylate vials in infants, consider the combined daily metabolic load of benzyl alcohol from all sources, including Atracurium Besylate and other drugs containing benzyl alcohol. 

Patients treated with Atracurium Besylate with renal or hepatic impairment might have higher metabolite concentrations than patients with normal renal and hepatic function. The level of neuromuscular blockade during long-term Atracurium Besylate administration should be monitored with a nerve stimulator to titrate the drug Atracurium Besylate administration to the patients’ needs and limit exposure to toxic metabolites.

There are reports of severe hypersensitivity reactions, including fatal and life-threatening anaphylactic reactions after administration of Atracurium Besylate injection. Due to the potential severity of such reactions, one should take appropriate precautions, such as the immediate availability of appropriate emergency treatment. 

Administration of Atracurium Besylate results in paralysis, leading to respiratory arrest and death, a progression that may likely happen in a patient for whom it is not intended. One should confirm the proper selection of the intended product and avoid confusion with other injectable solutions in critical care and other clinical settings.

Neuromuscular blockade in the conscious patient could lead to distress. Use Atracurium Besylate in the presence of appropriate sedation or general anaesthesia. One should monitor patients to ensure that the level of anaesthesia is adequate. 

Certain drugs might enhance the neuromuscular blocking action of Atracurium Besylate, including inhalational anaesthetics, antibiotics, magnesium salts, lithium, local anaesthetics, procainamide, and quinidine. One should use peripheral nerve stimulation and monitor the clinical signs of neuromuscular blockade to determine the adequacy of the level of neuromuscular blockade and the need to adjust the Atracurium Besylate dosage.

  

Note: All information mentioned in this article is provided just for informational, educational, and referential purposes only.

Atracurium Besylate- All you need to know about

Atracurium Besylate is also known as Atracurium Besilate. It is used with other medications to provide skeletal muscle relaxation during surgery or mechanical ventilation. Atracurium Besylate is an intermediate duration, non-depolarizing, skeletal muscle relaxant for intravenous administration. It is given via intravenous infusion. The standard strength of Atracurium Besylate is 25 mg. 

Dosage and administration 

Do not administer an Atracurium ampoule before unconsciousness has been induced to avoid distress to the patient. Do not mix Atracurium Besylate in the same syringe, or administer it simultaneously through the same needle, with alkaline solutions, e.g., barbiturate solutions. Administer Atracurium Besylate intravenously. Do not give Atracurium through intramuscular administration because such administration of the medicine may result in tissue irritation. The use of a peripheral nerve stimulator would facilitate Atracurium with other neuromuscular blocking agents, minimizing the possibility of an overdose and assisting in the evaluation of recovery.

The general dosage for adults

A dose of Atracurium infusion of 0.4 to 0.5 mg/kg is the initial recommended dose for most patients. Good conditions for non-emergency intubation can be expected in 2-2.5 minutes in most patients with this dose, with maximum neuromuscular block achieved approximately 3-5 minutes after injecting the medicine. Underbalanced anaesthesia, clinically required neuromuscular block generally lasts 20 to 35.

Atracurium Besylate is intensified by isoflurane or enflurane anaesthesia. The same initial dose of the medicine may use 0.4 to 0.5 mg/kg for intubation before administering these inhalation agents. However, if Atracurium is first administered under the steady-state of isoflurane or enflurane, reduce the initial dose of Atracurium besilate by approximately one third, i.e., to 0.25-0.35 mg/kg. With halothane, which has only a marginal potentiating effect on the medicine, consider the smaller dosage reductions.

Recommended doses of the medicine are 0.08 to 0.10 mg for maintenance of neuromuscular block during prolonged surgeries. Generally, the first maintenance dose required is 20 to 45 minutes after the initial Atracurium infusion, but clinical criteria should determine the need for maintenance doses. 

The general dosage for children

There is no requirement for adjustments of doses of Atracurium Besylate pediatric patients two years of age or older. A dose of 0.3-0.4 mg/kg is recommended as the initial dose for infants under halothane anaesthesia. In infants and children than in adults. Maintenance doses might be required with slightly greater frequency.

Dosage In special cases

An initial dose of the medicine of 0.3 to 0.4 mg/kg is recommended for adults, adolescents, children with significant cardiovascular disease. And adults, adolescents, children with any history (e.g. asthma), suggesting a greater risk of histamine release, give it slowly or in divided doses for 1 minute.

Overdosage

If an overdose happens, the doctor will monitor the patient for symptoms or worsening signs. One can minimize the chances of an overdose by carefully monitoring muscle twitch response to peripheral nerve stimulation. Excessive doses of the medicine can be expected to produce enhanced effects.

Atracurium mechanism of action

The salt Atracurium Besylate is a nondepolarizing skeletal muscle relaxant. Such nondepolarizing agents oppose the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end plate. The antagonism is inhibited, and the neuromuscular block is reversed by acetylcholinesterase inhibitors like neostigmine, pyridostigmine and edrophonium.

Atracurium can be used if muscle twitch response to peripheral nerve stimulation is monitored to assess the degree of relaxation of the muscle. 

The duration of neuromuscular block produced by this medicine is approx one-third to one-half of the block by d-tubocurarine, metocurine, and pancuronium at initially equal doses. As with other nondepolarizing neuromuscular blockers, the onset of paralysis decreases and the duration of maximum effect increases with increasing atracurium doses.   

Precautions

Before Atracurium infusion, ask the patient about any medical history or anaphylactic reactions. Moreover, the healthcare professionals should acknowledge the patient about the after-effects of having Atracurium infusion. 

Although Atracurium is a less potent histamine releaser than d-tubocurarine or metocurine, one must consider the possibility of substantial histamine release in sensitive individuals.

One should take necessary precautions while administering Atracurium to patients in whom substantial histamine release will be especially hazardous, e.g., patients with clinically significant cardiovascular disease. And patients with any history like severe anaphylactoid reactions suggesting a greater risk of histamine release. In such patients, the initial recommended dose is lower (0.3 to 0.4 mg/kg) than other patients. It should be administered slowly or in divided doses over one minute. 

Side effects of Atracurium

The common side effects of Atracurium Besylate are allergic reactions, itching, low blood pressure, skin redness, reactions at the injection site, etc. Medicine's severe side effects are  Severe anaphylactic reactions, paralysis, respiratory arrest, etc.

Price of Atracurium in India

Atracurium price offered by innovators or manufacturers is high as compared to the price offered by suppliers. In India, rare medicines like these are readily available and are cheap. Ikris Pharma Network is one such certified supplier in India delivering medicines and services in India and abroad.